{"id":"W2952422947","doi":"10.1136/annrheumdis-2019-eular.1466","title":"FRI0398 IXEKIZUMAB IS EFFECTIVE IN THE TREATMENT OF RADIOGRAPHIC AXIAL SPONDYLOARTHRITIS REGARDLESS OF THE LEVEL OF C-REACTIVE PROTEIN OR MAGNETIC RESONANCE IMAGING SCORES: 16-WEEK DATA FROM COAST-V AND COAST-W","year":2019,"lang":"en","type":"article","venue":"Annals of the Rheumatic Diseases","topic":"Spondyloarthritis Studies and Treatments","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":false,"ca_institutions":"University of Alberta","funders":"UCB Pharma; Pfizer; Eli Lilly and Company","keywords":"Medicine; Ankylosing spondylitis; Adalimumab; BASDAI; Sacroiliitis; Internal medicine; Ixekizumab; Placebo; Back pain; Population; Axial spondyloarthritis; Magnetic resonance imaging; Secukinumab; Visual analogue scale; Gastroenterology; Physical therapy; Tumor necrosis factor alpha; Disease; Pathology; Radiology","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001952526,0.0004699742,0.001325441,0.0003775242,0.0002783421,0.0005372275,0.0006735833,0.0007762375,0.002391836],"category_scores_gemma":[0.001637035,0.0002547564,0.001240546,0.0004093388,0.0004740393,0.000694196,0.0003256227,0.001213905,0.0005072745],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0004469061,"about_ca_system_score_gemma":0.0008242449,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.003997936,"about_ca_topic_score_gemma":0.008165484,"domain_scores_codex":[0.9993007,0.0002430598,0.0001024013,0.00009892863,0.0001245558,0.0001302291],"domain_scores_gemma":[0.9980693,0.0003905825,0.0005562726,0.0002731122,0.0002512338,0.0004594438],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.6336502,0.008561229,0.1221394,0.001492764,0.004572066,0.0006126358,0.0002902278,0.0008271633,0.04228541,0.0001668973,0.0156333,0.1697688],"study_design_scores_gemma":[0.1046724,0.2281281,0.635083,0.0003251336,0.001843644,0.002000986,0.0003789108,0.00097072,0.01126952,0.0001346428,0.01507555,0.0001173796],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9847398,0.008643041,0.0001830432,0.0003353497,0.00009269724,0.0001445924,0.003325264,0.00004649607,0.002489593],"genre_scores_gemma":[0.9878898,0.002839006,0.0005747905,0.0003243917,0.00009555159,0.00007259152,0.005418116,0.00002498598,0.002760892],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.003997936,"threshold_uncertainty_score":0.01032609,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.06489042340462008,"score_gpt":0.3073104009727469,"score_spread":0.2424199775681268,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}